Participants in the trial will receive RLS-0071 for seven or 14 days, either as a standalone therapy or in combination with ruxolitinib. Credit: Pormezz / Shutterstock.

US-based biopharmaceutical company ReAlta Life Sciences has dosed the first subject in its Phase II clinical trial of RLS-0071 for treating steroid-refractory acute graft-versus-host disease (aGvHD).

The open-label, dose-escalation study will assess the tolerability, safety, pharmacokinetics, pharmacodynamics, dosing and efficacy of RLS-0071 as a secondary treatment for aGvHD in patients who do not respond to steroid therapy.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Participants in the trial will receive RLS-0071 for seven or 14 days, either as a standalone therapy or in combination with the standard treatment ruxolitinib.

The study’s primary goals are to evaluate the safety and overall response rate in patients given RLS-0071.

RLS-0071 is an investigational therapeutic candidate based on ReAlta’s EPICC peptide platform, designed with a dual-targeting mechanism to modulate both complement and innate inflammatory pathways.

The US Food and Drug Administration (FDA) recently granted orphan drug and fast track designations to RLS-0071 for treating steroid-refractory aGvHD.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

ReAlta Life Sciences chief medical officer Kenji Cunnion said: “Haematopoietic stem cell transplantation is one of the most impactful treatments available for people with cancer, autoimmune disease, sickle cell disease and other life-threatening disorders.

“However, the procedure can quickly turn into a severe and life-threatening condition for those who are affected by acute graft-versus-host disease in which the transplanted immune cells attack the patient, leading to severe inflammation and tissue damage.

“We believe that RLS-0071 has the potential to be a powerful new tool to improve outcomes for individuals with this serious complication of transplantation.

“We aim to leverage RLS-0071’s unique dual mechanism-of-action to inhibit unwanted inflammatory side-effects from the donor cells.”

ReAlta is also carrying out Phase II trials of RLS-0071 for newborns with hypoxic-ischaemic encephalopathy and for patients hospitalised with acute exacerbations of chronic obstructive pulmonary disease.

The company was founded in 2018 and has operations in Norfolk, Virginia; and Aguadilla, Puerto Rico.

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now